Skip to content
  • Home
  • World News
  • Business
  • Aviation
195 news

195News

All the news that's fit to print

  • Home
  • World News
  • Business
  • Aviation
  • Toggle search form
  • Infillion Acquires Market Research Platform Phonic
    Infillion Acquires Market Research Platform Phonic Business
  • War in Ukraine, Analytics. Day 761 (part1): Mass Psychosis & Degradation of Russia
    War in Ukraine, Analytics. Day 761 (part1): Mass Psychosis & Degradation of Russia World News
  • Key Drivers, Major Trends and Opportunities
    Key Drivers, Major Trends and Opportunities Business
  • 52nd Session of the UN Human Rights Council
    52nd Session of the UN Human Rights Council World News
  • Prism Digital wins website development mandate for Carpe Diem
    Prism Digital wins website development mandate for Carpe Diem World News
  • War Day 138: war diaries w/Advisor to Ukraine President, Intel Officer @arestovych  & #Feygin
    War Day 138: war diaries w/Advisor to Ukraine President, Intel Officer @arestovych & #Feygin World News
  • Automotive Chargers and USB Data Hubs Market to Hit $ 196.88 Million by 2028 at 4.1% CAGR
    Automotive Chargers and USB Data Hubs Market to Hit $ 196.88 Million by 2028 at 4.1% CAGR World News
  • Fortun / Luminar Media Group Announces Debt Restructuring to Minimize Legacy Debt and Maximize Shareholder Value
    Fortun / Luminar Media Group Announces Debt Restructuring to Minimize Legacy Debt and Maximize Shareholder Value Business
TTC Oncology LLC Signs a Collaboration Agreement With Lantern Pharma

TTC Oncology LLC Signs a Collaboration Agreement With Lantern Pharma

Posted on March 15, 2023 By NewsEditor
TTC Oncology LLC Signs a Collaboration Agreement With Lantern PharmaTTC Oncology LLC Signs a Collaboration Agreement With Lantern Pharma

EDINA, Minn., March 15, 2023 (Newswire.com) - TTC Oncology ("TTC" or the "Company") announced the signing of a Collaboration Agreement (the "Agreement") with Lantern Pharma Inc. ("LTRN") to expand the clinical development of the TTC drug candidate TTC-352. The Phase-2 ready candidate, TTC-352, is an orally available small molecule being developed as a treatment for patients with metastatic estrogen receptor-positive ("ER+") breast cancer who have failed two or more prior therapies. TTC-352 is a first-in-class selective human ER partial agonist (ShERPA) that in metastatic disease causes ER to induce breast cancer cell death.

The collaboration will be powered by Lantern's artificial intelligence (AI) platform, RADR®, and its 25+ billion oncology-focused data points, 200+ advanced ML algorithms, as well as its four multi-faceted AI drug discovery and development modules. The initial aims of the collaboration will be to 1) identify biomarker or gene signatures to power potential patient selection for an upcoming TTC-352 Phase 2 clinical trial, 2) further characterize TTC-352's mechanism of action, and 3) discover additional treatment indications for TTC-352.

Breast cancer afflicts approximately 2.1 million women in the U.S. yearly with the majority of these cases being ER+, in which ER promotes tumor growth. Patients with ER+ breast cancer are initially treated with endocrine therapy, which blocks the tumorigenic actions of ER. Unfortunately, almost half of all patients who undergo endocrine therapy develop endocrine-resistant metastatic disease and will need chemotherapy as a last resort. TTC-352 provides an alternative approach without the toxicity associated with chemotherapy. 

Under the terms of the collaboration, Lantern Pharma is receiving an exclusive right to license TTC-352, including any collaboration intellectual property (IP), during an exclusive option period. Additionally, Lantern and TTC will each participate in upfront, milestone, and royalty payments in the event a third party licenses IP resulting from the collaboration. No further financial details were disclosed.

About Lantern Pharma

Lantern Pharma ("LTRN") is a clinical-stage oncology-focused biopharmaceutical company leveraging its proprietary RADR® AI and machine learning platform to discover biomarker signatures that identify patients most likely to respond to its pipeline of genomically-targeted therapeutics. By targeting drugs to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, Lantern's approach represents the potential to deliver best-in-class outcomes. For more information, please visit the company's website at www.lanternpharma.com.

About TTC Oncology LLC

TTC Oncology is an emerging biotechnology company founded in 2015. TTC Oncology's mission is to develop and bring to market a novel, small-molecule therapy, TTC-352, to address the unmet needs of breast cancer patients. TTC has a license from the University of Illinois at Chicago covering the therapy. https://ttconcology.com/ TTC is currently raising funds to complete Phase II studies. 

Contact Information:
Joe Cunningham
CFO
[email protected]
6129911778


Original Source: TTC Oncology LLC Signs a Collaboration Agreement With Lantern Pharma TTC Oncology LLC Signs a Collaboration Agreement With Lantern Pharma

The post TTC Oncology LLC Signs a Collaboration Agreement With Lantern Pharma first appeared on Social Gov.

Business

Post navigation

Previous Post: Diverge Health Launched to Build Upon a Decade of Experience Serving Underserved Patients in New York
Next Post: Augmenta acquired by CNH Industrial

Related Posts

  • The Future of Health Competition Winner Announced
    The Future of Health Competition Winner Announced Business
  • AVID teams up with SunCulture on its innovative climate impact investing platform
    AVID teams up with SunCulture on its innovative climate impact investing platform Business
  • FlowForge Raises .2M Seed Round From Cota Capital and Open Core Ventures to Solve the Challenges of IT/OT Convergence
    FlowForge Raises $7.2M Seed Round From Cota Capital and Open Core Ventures to Solve the Challenges of IT/OT Convergence Business
  • Sugar Free Mints Market Trend to Reflect Tremendous Growth Potential With A Highest CAGR by 2031
    Sugar Free Mints Market Trend to Reflect Tremendous Growth Potential With A Highest CAGR by 2031 Business
  • Amyotrophic Lateral Sclerosis (ALS) Market to Reach US$ 709.7 Million by 2033, at CAGR of 3.68% from 2023 to 2033
    Amyotrophic Lateral Sclerosis (ALS) Market to Reach US$ 709.7 Million by 2033, at CAGR of 3.68% from 2023 to 2033 Business
  • Private Practice Physical Therapist Joins Hands-On Diagnostics to Boost Revenue
    Private Practice Physical Therapist Joins Hands-On Diagnostics to Boost Revenue Business
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
« Apr    
last celebrity gossip
Gossip Stone - celebrity life and gossip

Recent Posts

  • Volatus annonce la clôture d’un placement VIE entièrement souscrit de 3 000 000 $May 13, 2025
  • Kenny Dewan Launches Mahalo Recovery FoundationMay 13, 2025
  • Growth Drivers, Share, And TrendsMay 13, 2025
  • Watlow® Accelerates Growth in Malaysia with Expanded Facility & Long-Term Commitment to SE Asia’s Industrial InnovationMay 12, 2025
  • TRIO announces brand evolution focused on AI, creativity and human connectionMay 12, 2025
Brand Values Content
VUGA Enterprises - media network PR & Marketing
  • eVTOL Aircraft Market USD 4.46 Billion by 2030, Driven Due to Rising Frequency of Cervical Spondylosis Among Corporate
    eVTOL Aircraft Market USD 4.46 Billion by 2030, Driven Due to Rising Frequency of Cervical Spondylosis Among Corporate Aviation
  • Biden-Harris Administration Announces More Than 0 Million in Bipartisan Infrastructure Law Funding to Modernize Airports in 37 States
    Biden-Harris Administration Announces More Than $240 Million in Bipartisan Infrastructure Law Funding to Modernize Airports in 37 States Aviation
  • TutorABC Partners with the British Office Taipei to Sponsor the Prestigious Chevening Scholarship Program
    TutorABC Partners with the British Office Taipei to Sponsor the Prestigious Chevening Scholarship Program Business
  • War Day 556: How Will Ukranian Missiles Change This War?
    War Day 556: How Will Ukranian Missiles Change This War? World News
  • Pulse Ingredients Market Size, Share And Growth Analysis For 2023-2032
    Pulse Ingredients Market Size, Share And Growth Analysis For 2023-2032 World News
  • Global Advanced Composites Market Size to Hit .9Bn by 2028
    Global Advanced Composites Market Size to Hit $68.9Bn by 2028 World News
  • Secretary Antony J. Blinken And Egyptian Foreign Minister Sameh Shoukry Before Their Meeting
    Secretary Antony J. Blinken And Egyptian Foreign Minister Sameh Shoukry Before Their Meeting World News
  • Credit Union 1 Finalizes Emory Alliance Credit Union Merger, Increasing Asset Size to .6 Billion
    Credit Union 1 Finalizes Emory Alliance Credit Union Merger, Increasing Asset Size to $1.6 Billion Business
aerospace company
stem cell clinic in kiev
medical spa in miami
Fashion TV free

Copyright © 2023 195 News. All Rights Reserved by Coolaser | Partner of VUGA Enterprises |  Advertising: Get Published

Powered by .